dyslipidemia


Also found in: Medical, Acronyms, Wikipedia.

dys·lip·i·de·mi·a

 (dĭs-lĭp′ĭ-dē′mē-ə)
n.
An abnormal concentration of lipids or lipoproteins in the blood.


dys·lip′i·de′mic (-mĭk) adj.
Translations

dyslipidemia

n dislipidemia
Mentioned in ?
References in periodicals archive ?
Though most frequent dyslipidemia in NAFLD was low serum HDL-C followed by hypertriglyceridemia, only serum nonHDL-C was statistically different amongst all the grades of NAFLD.
M2 EQUITYBITES-November 13, 2017-Zydus passes regulatory approval in Mexico for Lipaglyn for patients suffering from hypertriglyceridemia and diabetic dyslipidemia
M2 PHARMA-November 13, 2017-Zydus passes regulatory approval in Mexico for Lipaglyn for patients suffering from hypertriglyceridemia and diabetic dyslipidemia
Dyslipidemia and tobacco smoking synergistically increase serum manganese
In the studies, Praluent (alirocumab) when administered on top of maximally tolerated doses (MTD) of statins significantly reduced low-density lipoprotein cholesterol (LDL-C), the primary endpoint of the ODYSSEY-DM INSULIN study, and was superior to usual care in reducing non-high-density lipoprotein cholesterol (non-HDL-C), the primary endpoint of the ODYSSEY-DM DYSLIPIDEMIA study.
Objective: To determine the frequency of dyslipidemia in patients with lupus nephritis and its association with the degree of proteinuria.
HIV populations everywhere end up with high rates of dyslipidemia, however it's measured.
1) To study the lipid levels in patients with lichen planus and controls, to find the association of lichen planus with dyslipidemia and to find the association of lichen planus with metabolic syndrome.
At the same time, the state of hemostatic characteristics of platelets at early stages of dyslipidemia development, leading to atherosclerosis, is still studied quite insufficiently.
com)-- Dyslipidemia Drugs Market - Global Dyslipidemia Drug Classes Analysis and Forecast 2013-2020, estimates the global dyslipidemia drugs market decline to reach nearly USD 9.
Global Markets Direct's, 'Mixed Dyslipidemia - Pipeline Review, H1 2016', provides an overview of the Mixed Dyslipidemia pipeline landscape.
Conclusion: It is concluded from the study that non-diabetic, normotensive albeit obese subjects have higher frequency of dyslipidemia as it was found in 84% of the study participants and therefore are at a higher risk for CVD.